ClinicalTrials.gg
RecruitingNCT07472842Updated Aug 26, 2026

Study on the Outcomes of Patients Treated in Gynecological Emergency Departments for Pelvic Endometriosis or Suspected Pelvic Endometriosis

An interventional study of Emergency care for endometriosis in Endometriosis, Pelvic Pain Syndrome and Chronic Gynaecological Disease, sponsored by Centre Hospitalier Intercommunal Creteil. Recruiting at 1 site in France. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-26.

Sponsored by Centre Hospitalier Intercommunal Creteil · Not applicable, Interventional, and Diagnostic

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year later.
Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Study summary

Adult patients consulting the gynecological emergency department of CHI Créteil during the inclusion period for endometriosis or symptoms suggestive of endometriosis

Read the detailed description

Endometriosis is defined as the presence outside the uterine cavity of tissue similar to the uterine mucosa, which will be affected by hormonal changes during each subsequent menstrual cycle. Endometriosis is thus responsible for pelvic pain, which can be particularly incapacitating, as well as other symptoms depending on the location of the lesions. In some cases, endometriosis is also responsible for infertility. Symptoms have a considerable impact on the quality of life of sufferers, affecting not only their personal and marital lives, but also their professional and social lives.

02

Conditions studied

  • Endometriosis
  • Pelvic Pain Syndrome
  • Chronic Gynaecological Disease

Keywords

  • infertility
  • dysmenorrhea
  • pelvic pain
03

In context

Endometriosis

920 studies on the registry are indexed under Endometriosis; 266 are open to participants now.

This study's planned enrollment of 200 is above the median of 67 across 540 interventional studies indexed under Endometriosis.

Browse Endometriosis studies →

Lead sponsor

Centre Hospitalier Intercommunal Creteil is the lead sponsor of 131 studies on the registry; 36 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patient (aged 18 or over)
  • Patient consulting the gynecological emergency department at Créteil Hospital for
  • Known endometriosis or
  • Symptoms suggestive of endometriosis: dysmenorrhea, pelvic pain, cyclic dysuria, dyspareunia, cyclic dyschezia, infertility, rectal bleeding, chest pain, catamenial hematuria
  • Patient who speaks French and is able to understand the information sheet

Exclusion criteria

Exclusion Criteria:

  • Minor or menopausal patient
  • Pregnant and breastfeeding patient
  • Other reason for consultation
  • Patient refusal
  • Patient not affiliated with a social security system
  • Patient cannot be contacted for the 3-months questionnaire
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Other
    Impact of emergency room care on endometriosis or its diagnosis

    Diagnostic Test: Emergency care for endometriosis

Interventions

  • Diagnostic testEmergency care for endometriosis

    Emergency care for endometriosis * Introduction of specific treatment for endometriosis * Scheduled or completed specialist consultation (gynecologist, surgeon, midwife, radiologist) * Pelvic imaging examination scheduled or completed since the gynecological emergency consultation

06

What researchers measure

Primary outcomes

  1. Assessing the impact of treatment in gynecological emergency departments on patients with endometriosis or suspected endometriosis

    Composite criteria : number of specific hormonal or analgesic treatment introduiced for endometriosis according to ESHRE guideline endometriosis

    Time frame: At 3 months

  2. Assessing the impact of treatment in gynecological emergency departments on patients with endometriosis or suspected endometriosis

    Composite criteria : number of scheduled or completed specialist consultation (gynaecologist, surgeon, midwife, radiologist)

    Time frame: At 3 months

  3. Assessing the impact of treatment in gynecological emergency departments on patients endometriosis or suspected endometriosis

    Composite criteria : number of Pelvic imaging recommanded for diagnostic or follow up of endometriosis, according to ESHRE guideline, scheduled or completed since the gynecological emergency consultation

    Time frame: At 3 months

  4. Assessing the impact of deprivation on the future of patients after consultation at gynaecological emergency departments.

    EPICE Scores (Evaluation of Deprivation and Inequalities in Health Examination Centers)

    Time frame: At 3 months

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2025 to primary completion in Jan 2026, 2 months.

Of 196 non-industry interventional studies with no phase under Endometriosis, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 44. This study's 2 months is below that.

Counting every sponsor, half of 211 studies reached it within 25 months; a quarter within 13 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 25, 2025
First posted
Mar 16, 2026
StartActual
Oct 16, 2025
Primary completionActual
Jan 15, 2026
CompletionEst.
Nov 15, 2026
Last update
Aug 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07472842
Responsible party
Sponsor
First posted
Mar 16, 2026
Start date
Oct 16, 2025
Primary completion
Jan 15, 2026
Completion
Nov 15, 2026 (estimated)
Last update
Aug 26, 2026

Study contacts

Yann SALHI, MD
Contact
yann.salhi@chicreteil.fr
01 57 02 20 00 ext. 8456

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion